Brokerages Set Acelyrin, Inc. (NASDAQ:SLRN) Target Price at $23.67

Acelyrin, Inc. (NASDAQ:SLRN – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the seven research firms that are covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price objective among […]

Related Keywords

Shao Lee Lin ,Hidradenitis Suppurativa ,Wells Fargo Company ,Acelyrin Company Profile ,Jpmorgan Chase Co ,Morgan Stanley ,Vanguard Group Inc ,Jefferies Financial Group ,Bio Partners ,Ayurmaya Capital Management Company ,Nasdaq ,Citigroup ,Acelyrin Inc ,Get Free Report ,Financial Group ,Lee Lin ,Maya Capital Management Company ,Get Free ,Psoriatic Arthritis ,Acelyrin Daily ,Acelyrin ,Nasdaq Slrn ,Slrn ,Medical ,Ratings ,Consensus ,